Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Earns “Buy” Rating from Jefferies Group LLC

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)‘s stock had its “buy” rating reiterated by equities researchers at Jefferies Group LLC in a research report issued on Thursday. They currently have a $16.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $18.00. Jefferies Group LLC’s price objective suggests a potential upside of 101.01% from the company’s current price. Jefferies Group also issued estimates for Bellicum Pharmaceuticals’ Q3 2017 earnings at ($0.74) EPS, Q4 2017 earnings at ($0.74) EPS, FY2017 earnings at ($3.02) EPS, FY2018 earnings at ($2.68) EPS, FY2019 earnings at ($3.02) EPS, FY2020 earnings at ($1.20) EPS and FY2021 earnings at ($0.04) EPS.

A number of other equities research analysts have also recently issued reports on BLCM. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $31.00 target price on shares of Bellicum Pharmaceuticals in a report on Tuesday, June 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $35.00 target price on shares of Bellicum Pharmaceuticals in a report on Monday, June 26th. Ladenburg Thalmann Financial Services set a $31.00 target price on shares of Bellicum Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, June 24th. Raymond James Financial, Inc. reaffirmed a “buy” rating on shares of Bellicum Pharmaceuticals in a report on Tuesday, June 27th. Finally, BidaskClub cut shares of Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, July 6th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $26.20.

Shares of Bellicum Pharmaceuticals (BLCM) traded up 4.05% during mid-day trading on Thursday, hitting $7.96. The stock had a trading volume of 1,081,491 shares. The stock’s 50-day moving average price is $11.38 and its 200-day moving average price is $12.32. The stock’s market capitalization is $264.48 million. Bellicum Pharmaceuticals has a 12-month low of $7.59 and a 12-month high of $23.11.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.65) by $0.09. Bellicum Pharmaceuticals had a negative return on equity of 70.74% and a negative net margin of 17,957.31%. During the same quarter last year, the company earned ($0.61) EPS. On average, equities analysts anticipate that Bellicum Pharmaceuticals will post ($2.95) EPS for the current fiscal year.

WARNING: “Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Earns “Buy” Rating from Jefferies Group LLC” was published by Transcript Daily and is the property of of Transcript Daily. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://transcriptdaily.com/2017/08/13/bellicum-pharmaceuticals-inc-nasdaqblcm-earns-buy-rating-from-jefferies-group-llc.html.

In other news, CFO Alan A. Musso sold 6,311 shares of the company’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $12.24, for a total value of $77,246.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Ken Moseley sold 13,823 shares of the company’s stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $12.26, for a total transaction of $169,469.98. Following the completion of the sale, the vice president now directly owns 14,314 shares in the company, valued at $175,489.64. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,571 shares of company stock worth $367,295. 23.30% of the stock is owned by insiders.

Several large investors have recently modified their holdings of the stock. State Street Corp boosted its position in Bellicum Pharmaceuticals by 4.9% in the fourth quarter. State Street Corp now owns 326,037 shares of the biopharmaceutical company’s stock valued at $4,442,000 after buying an additional 15,142 shares in the last quarter. Renaissance Technologies LLC bought a new position in Bellicum Pharmaceuticals during the fourth quarter valued at $1,129,000. Teachers Advisors LLC boosted its position in Bellicum Pharmaceuticals by 5.5% in the fourth quarter. Teachers Advisors LLC now owns 35,608 shares of the biopharmaceutical company’s stock valued at $485,000 after buying an additional 1,844 shares in the last quarter. Fox Run Management L.L.C. bought a new position in Bellicum Pharmaceuticals during the first quarter valued at $171,000. Finally, Wells Fargo & Company MN boosted its position in Bellicum Pharmaceuticals by 91.0% in the first quarter. Wells Fargo & Company MN now owns 76,081 shares of the biopharmaceutical company’s stock valued at $939,000 after buying an additional 36,242 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply